Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NovaBay Pharmaceuticals (NBY) Gross Margin (2016 - 2025)

Historic Gross Margin for NovaBay Pharmaceuticals (NBY) over the last 13 years, with Q3 2025 value amounting to 8.06%.

  • NovaBay Pharmaceuticals' Gross Margin changed N/A to 8.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 78.77%, marking a year-over-year increase of 78500.0%. This contributed to the annual value of 66.26% for FY2024, which is 80700.0% up from last year.
  • Per NovaBay Pharmaceuticals' latest filing, its Gross Margin stood at 8.06% for Q3 2025.
  • NovaBay Pharmaceuticals' Gross Margin's 5-year high stood at 100.0% during Q1 2023, with a 5-year trough of 8.06% in Q3 2025.
  • In the last 5 years, NovaBay Pharmaceuticals' Gross Margin had a median value of 64.17% in 2024 and averaged 61.96%.
  • As far as peak fluctuations go, NovaBay Pharmaceuticals' Gross Margin tumbled by -210200bps in 2022, and later skyrocketed by 445800bps in 2023.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Gross Margin stood at 52.88% in 2021, then dropped by -9bps to 48.17% in 2022, then rose by 7bps to 51.55% in 2023, then grew by 29bps to 66.26% in 2024, then plummeted by -88bps to 8.06% in 2025.
  • Its Gross Margin was 8.06% in Q3 2025, compared to 66.26% in Q4 2024 and 66.33% in Q2 2024.